Merck KGaA and Pfizer’s Bavencio (avelumab) + Inlyta (axitinib) Receive FDA’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

 Merck KGaA and Pfizer’s Bavencio (avelumab) + Inlyta (axitinib) Receive FDA’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Merck KGaA and Pfizer’s Bavencio (avelumab) + Inlyta (axitinib) Receive FDA’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Shots:

  • The approval is based on P-III JAVELIN Renal 101 study (NCT02684006) results assessing bavencio (avelumab) + Inlyta (axitinib) vs sunitinib in 886 patients in a ratio (1:1) with untreated advanced RCC regardless of tumor PD-L1 expression   
  • The P-III JAVELIN Renal 101 study results: improvement in PFS (13.8 vs 8.4mos.); ORR (51.4% vs 25.7%); published in The New England Journal of Medicine
  • Bavencio (avelumab) is a PD-L1 antibody, developed under the co-development and co-commercialization deal b/w Merck KGaA & Pfizer in 2014 & Inlyta is a tyrosine kinase inhibitor indicated for advanced RCC. The combination is under regulatory review in EU & Japan

Click here to read full press release/ article | Ref: Pfizer | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post